Histological Classification of Pancreatic Neuroendocrine Tumours: Optimising the Ki67 System Abstract #1239

Introduction: Pancreatic neuroendocrine tumours are graded using the Ki67 antigen in accordance with the WHO 2010 classification. Despite the system’s widespread use, a wide variety of tumour behaviours have been described leading to various proposed revisions.
Aim(s): To investigate: a) the use of 5% rather than 2% as the boundary between Grades 1 and 2, b) the use of 55% rather than 20% as the boundary between Grades 2 and 3, c) the subdivision of Grade 3 using poorly vs well-differentiated appearances.
Materials and methods: Of 223 patients who visited our institution between 2004 and 2013, Ki67 values were known for 168. Where data was available for the pancreas and liver metastases, the highest value was used. The significance of each system was investigated using Kaplan-Meier survival curves and specific Ki67 values searched for using ROC.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Pathology, grading, staging
Presenting Author: Logan Mills
Keywords: G3

To read results and conclusion, please login ...

Further abstracts you may be interested in

#890 Prognostic Validity of the WHO 2010 TNM Staging and Grading Criteria for Pancreatic Neuroendocrine Tumors
Introduction: The TNM staging and grading system developed by the WHO was designed to help prognosticate patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Mr Logan E Mills
#893 The Role of Primary Resection and Hepatic Resection in the Management of Metastatic Pancreatic Neuroendocrine Tumors with Irresectable Liver Metastases
Introduction: More than 40% of pancreatic neuroendocrine tumor (PNET) patients have liver metastases (LM) at diagnosis. Whilst it is agreed that, where possible, curative surgery offers the best outcomes, the role of debulking surgery in the context of irresectable LM remains unclear.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Surgical treatment
Presenting Author: Mr Logan E Mills
Keywords: liver
#1209 Pancreatic Neuroendocrine Incidentalomas: When is Surgery in the Patient’s Best Interests?
Introduction: Small PNETs, many of which are diagnosed incidentally, pose a management dilemma. Whilst resection offers curative outcomes, the risks of surgery have led many to adopt surveillance strategies. 2cm is often used as a threshold for malignancy, but reports suggest that this value may not be valid.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: Logan Mills
Keywords: PNET
#1777 Tumour Size Is Not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort
Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Logan Mills
#684 Clinical Characteristics and Survival of Neuroendocrine Tumors of Unknown Primary
Introduction: NETs of unknown primary account for 10-15% of NETs. There is limited published literature on this group of NETs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Dr Raj Srirajaskanthan